Vaishali Kapoor
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Vaishali Kapoor has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Arpine Khudanyan
Washington University School of Medicine in St. Louis, UNITED STATES
1 shared publicationBuck E. Rogers
Department of Radiation Oncology, Washington University in St. Louis, St. Louis, Missouri
1 shared publication- David Y. A. Dadey
Washington University in St. Louis School of Medicine, St. Louis, MO
1 shared publication - Dennis E. Hallahan
Department of Radiation Oncology, Washington University in St. Louis, St. Louis, Missouri
1 shared publication - Dinesh Thotala
Radiation Oncology - Cancer Biology, Washington Univ. in St. Louis, Saint Louis, MO
1 shared publication Kelly Hoye
Medical Guidance Systems
1 shared publication
Latest Publications
- Open Access
- 21 July 2016
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 57 (12) , 1991-1997
Tumor-Specific Binding of Radiolabeled PEGylated GIRLRG Peptide: A Novel Agent for Targeting Cancers
Cancer specific targeting sparing normal tissues would significantly enhance cancer therapy outcomes and reduce cancer-related mortality. One approach is to target receptors and/or molecules that are specifically expressed on cancer cells. Peptides as cancer-specific targeting agents offer advantages such as ease of synthesis, low antigenicity and enhanced diffusion into tissues. Glucose regulated protein 78 (GRP78) is an endoplasmic reticulum stress chaperone that regulates the unfolded protein response and is over expressed in various cancers. In this study we evaluated GIRLRG peptide that specifically targets GRP78 for cancer specific binding (in vitro) and non-invasive tumor imaging (in vivo). Methods: GIRLRG peptide was modeled into the GRP78 ATPase domain using computational modeling. Surface Plasmon Resonance studies were performed to determine the affinity of GIRLRG peptide to GRP78 protein. GIRLRG was conjugated with PEG to prolong its circulation in mice. Tumor binding efficacy of PEG-GIRLRG peptide was evaluated in nude mice bearing heterotopic cervical (HT3), esophageal (OE33), pancreatic (BXPC3), lung (A549) and glioma (D54) tumors. NanoSPECT/CT imaging of the mice was performed 48 h and 72 h after injecting with 111Indium (111In) labeled PEG-GIRLRG or PEG-control peptide. Post-SPECT biodistribution studies were performed 96 h post-injection of the radiolabeled peptides. Results: Using molecular modeling and surface plasmon resonance, we identified that GIRLRG was binding with a KD of 2.16 X 10-3 M in the ATPase domain of GRP78. GIRLRG peptide specifically bound to cervical, lung, esophageal and glioma cells. SPECT imaging revealed that 111In-PEG-GIRLRG specifically bound to cervical, esophageal, pancreatic, lung and brain tumors. Post SPECT biodistribution data also validated the SPECT imaging results. Conclusion: GIRLRG peptide specifically binds to the ATPase domain of GRP78. Radiolabeled PEG-GIRLRG could be used to target various cancers. Further studies would be required to translate PEG-GIRLRG peptide into the clinic.
- 21 July 2016
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 57 (12) , 1991-1997
Open AccessTumor-Specific Binding of Radiolabeled PEGylated GIRLRG Peptide: A Novel Agent for Targeting Cancers
Cancer specific targeting sparing normal tissues would significantly enhance cancer therapy outcomes and reduce cancer-related mortality. One approach is to target receptors and/or molecules that are specifically expressed on cancer cells. Peptides as cancer-specific targeting agents offer advantages such as ease of synthesis, low antigenicity and enhanced diffusion into tissues. Glucose regulated protein 78 (GRP78) is an endoplasmic reticulum stress chaperone that regulates the unfolded protein response and is over expressed in various cancers. In this study we evaluated GIRLRG peptide that specifically targets GRP78 for cancer specific binding (in vitro) and non-invasive tumor imaging (in vivo). Methods: GIRLRG peptide was modeled into the GRP78 ATPase domain using computational modeling. Surface Plasmon Resonance studies were performed to determine the affinity of GIRLRG peptide to GRP78 protein. GIRLRG was conjugated with PEG to prolong its circulation in mice. Tumor binding efficacy of PEG-GIRLRG peptide was evaluated in nude mice bearing heterotopic cervical (HT3), esophageal (OE33), pancreatic (BXPC3), lung (A549) and glioma (D54) tumors. NanoSPECT/CT imaging of the mice was performed 48 h and 72 h after injecting with 111Indium (111In) labeled PEG-GIRLRG or PEG-control peptide. Post-SPECT biodistribution studies were performed 96 h post-injection of the radiolabeled peptides. Results: Using molecular modeling and surface plasmon resonance, we identified that GIRLRG was binding with a KD of 2.16 X 10-3 M in the ATPase domain of GRP78. GIRLRG peptide specifically bound to cervical, lung, esophageal and glioma cells. SPECT imaging revealed that 111In-PEG-GIRLRG specifically bound to cervical, esophageal, pancreatic, lung and brain tumors. Post SPECT biodistribution data also validated the SPECT imaging results. Conclusion: GIRLRG peptide specifically binds to the ATPase domain of GRP78. Radiolabeled PEG-GIRLRG could be used to target various cancers. Further studies would be required to translate PEG-GIRLRG peptide into the clinic.